Arrowstreet Capital
ONC

Arrowstreet Capital’s BeOne Medicines Ltd ONC Stock Holding History

Arrowstreet Capital’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8M Buy
110,586
+54,260
+96% +$17.6M 0.02% 612
2025
Q4 		$17.1M Buy
56,326
+592
+1% +$194K 0.01% 782
2025
Q3 		$19M Buy
55,734
+53,649
+2,573% +$16.3M 0.01% 748
2025
Q2 		$505K Sell
2,085
-36,777
-95% -$9.02M ﹤0.01% 1748
2025
Q1 		$10.6M Buy
+38,862
New +$9.09M 0.01% 796
2021
Q1 		– Sell
-30,782
Closed -$7.95M – 2583
2020
Q4 		$7.95M Buy
+30,782
New +$8.47M 0.01% 982
2018
Q4 		– Sell
-49,393
Closed -$8.51M – 1533
2018
Q3 		$8.51M Sell
49,393
-3,207
-6% -$539K 0.02% 441
2018
Q2 		$8.09M Buy
+52,600
New +$9.38M 0.02% 454

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital's ONC Position: Q1 2026 in Review

Arrowstreet Capital increased its BeOne Medicines Ltd (ONC) stake by 96% in Q1 2026, buying an estimated $17.6M and bringing the position to 110,586 shares worth $32.8M. The position accounts for 0.02% of the portfolio, ranked #612.

Arrowstreet Capital first reported a position in ONC in Q2 2018 and has held it in 8 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Arrowstreet Capital held 110,586 shares of BeOne Medicines Ltd worth $32.8M as of Q1 2026.
  • Arrowstreet Capital bought 54,260 BeOne Medicines Ltd shares in Q1 2026, an estimated $17.6M.
  • BeOne Medicines Ltd made up 0.02% of Arrowstreet Capital's portfolio in Q1 2026, its #612 holding.
  • Arrowstreet Capital first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 8 quarters since.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.